Company intelligence / Profile preview

Wuhan Ruijian Pharmaceutical Technology

Wuhan, Hubei Sheng, Chinaapp.dealroom.co ↗

Ownership: Private
Development stage: Other

Overview

Wuhan Ruijian has developed NouvNeu001, the world’s first universal cell therapy product based on chemical induction to enter the clinical stage for Parkinson's disease. The product uses iPSC-derived dopamine neural precursor cells to address dopaminergic neuron loss in PD and is designed to improve both dopamine secretion and the local cellular environment. Clinical trial approval was granted in August 2023.

Therapeutic areas: NeurologyOther
Modalities: Cell therapyInduced pluripotent stem cell derived therapy
Industry: Biotech

Beyond the preview

Go deeper on Wuhan Ruijian Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Ruijian Pharmaceutical Technology.

Explore the full profile